Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
25+ transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Christensen Jamie | EVP & Chief Scientific Officer | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 17,021 | Not reported | No price reported | 0Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Christensen Jamie | EVP & Chief Scientific Officer | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 81,480 | Not reported | No price reported | 17,021Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Christensen Jamie | EVP & Chief Scientific Officer | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 56,495 | Not reported | No price reported | 98,501Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Johnson Craig A | Director | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 6,808 | Not reported | No price reported | 0Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Johnson Craig A | Director | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 4,444 | Not reported | No price reported | 6,808Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Johnson Craig A | Director | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 6,021 | Not reported | No price reported | 11,252Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Gallagher Carol Giltner | Director | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 6,808 | Not reported | No price reported | 0Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Gallagher Carol Giltner | Director | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 7,555 | Not reported | No price reported | 6,808Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Sandler Alan B. | Chief Medical Officer | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 17,021 | Not reported | No price reported | 0Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Sandler Alan B. | Chief Medical Officer | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 52,297 | Not reported | No price reported | 17,021Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Sandler Alan B. | Chief Medical Officer | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 10,547 | Not reported | No price reported | 69,318Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Moriarty John B | Chief Legal Officer | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 71,660 | Not reported | No price reported | 0Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Moriarty John B | Chief Legal Officer | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 675 | Not reported | No price reported | 71,660Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Hickey Benjamin | EVP, Chief Commercial Officer | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 17,021 | Not reported | No price reported | 0Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Hickey Benjamin | EVP, Chief Commercial Officer | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 72,206 | Not reported | No price reported | 17,021Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Hickey Benjamin | EVP, Chief Commercial Officer | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 27,801 | Not reported | No price reported | 89,227Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Sharp Shalini | Director | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 6,808 | Not reported | No price reported | 0Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Sharp Shalini | Director | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 5,252 | Not reported | No price reported | 6,808Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Sharp Shalini | Director | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 4,162 | Not reported | No price reported | 12,060Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Davis Aaron I. | Director | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 6,808 | Not reported | No price reported | 0Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Davis Aaron I. | Director | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 4,444 | Not reported | No price reported | 6,808Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Davis Aaron I. | Director | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 43,073 | Not reported | No price reported | 11,252Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Martinez Maria E | Director | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 6,808 | Not reported | No price reported | 0Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Martinez Maria E | Director | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 4,444 | Not reported | No price reported | 6,808Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 | |
| Martinez Maria E | Director | Mirati Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 6,021 | Not reported | No price reported | 11,252Direct | Form 4 filed 23 Jan 2024, on sec.gov (opens in a new tab)Filed 23 Jan 2024 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.